CAV3 Antibody



PACO19259

Product Information

Size:

50ul

Reactivity:

Human

Source:

Rabbit

Isotype:

lgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:1000-1:5000, WB:1:500-1:2000, IHC:1:50-1:200

Protein Background:

A global transcription regulator. Complexes with cyclic AMP (cAMP) which allosterically activates DNA binding (to consensus sequence 5'-AAATGTGATCTAGATCACATTT-3') to directly regulate the transcription of about 300 genes in about 200 operons and indirectly regulate the expression of about half the genome. There are 3 classes of CRP promoters; class I promoters have a single CRP-binding site upstream of the RNA polymerase (RNAP)-binding site, whereas in class II promoters the single CRP- and RNAP-binding site overlap, CRP making multiple contacts with RNAP. Class III promoters require multiple activator molecules, including at least one CRP dimer. It can act as an activator, repressor, coactivator or corepressor. Induces a severe bend in DNA (about 87 degrees), bringing upstream promoter elements into contact with RNAP. Acts as a negative regulator of its own synthesis as well as for adenylate cyclase (cyaA), which generates cAMP. High levels of active CRP are detrimental to growth.

Gene ID:

CAV3

Uniprot

P56539

Synonyms:

caveolin 3


Immunogen:

Synthetic peptide of human CAV3.


Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol


Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO19259(CAV3 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 10%SDS-PAGE, Lysate: 40 μ g, Lane: Human fetal muscle tissue, Primary antibody: PACO19259(CAV3 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 15 seconds.



The image on the left is immunohistochemistry of paraffin-embedded Human gastic cancer tissue using PACO19259(CAV3 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).